Finerenone produced positive Phase III results in adults with chronic kidney disease caused by glomerular diseases without diabetes, according to the FIND-CKD trial. The study reported that finerenone significantly slowed kidney function decline and lowered cardiovascular risk. As a non-steroidal mineralocorticoid receptor antagonist, finerenone targets mineralocorticoid-driven inflammation and fibrosis pathways that contribute to CKD progression. The trial is positioned as one of the larger renal outcome studies in the non-diabetic CKD space, strengthening the evidence base for physicians deciding on long-term kidney and heart protection strategies. The next steps will likely include regulatory and guideline implications and head-to-head comparisons against other kidney-protective regimens used in glomerular disease phenotypes.